264 related articles for article (PubMed ID: 33070295)
21. Prognostic value of inflammatory response biomarkers using peripheral blood and [18F]-FDG PET/CT in advanced NSCLC patients treated with first-line chemo- or immunotherapy.
Seban RD; Assié JB; Giroux-Leprieur E; Massiani MA; Bonardel G; Chouaid C; Deleval N; Richard C; Mezquita L; Girard N; Champion L
Lung Cancer; 2021 Sep; 159():45-55. PubMed ID: 34311344
[TBL] [Abstract][Full Text] [Related]
22.
Wu X; Huang Y; Li Y; Wang Q; Wang H; Jiang L
Ann Nucl Med; 2019 Sep; 33(9):647-656. PubMed ID: 31165974
[TBL] [Abstract][Full Text] [Related]
23. Primary tumor standardized uptake value (SUVmax) measured on
Hui Z; Wei F; Ren H; Xu W; Ren X
J Cancer Res Clin Oncol; 2020 Oct; 146(10):2595-2605. PubMed ID: 32494919
[TBL] [Abstract][Full Text] [Related]
24. Predictive and Prognostic Role of Metabolic Response in Patients With Stage III NSCLC Treated With Neoadjuvant Chemotherapy.
Castello A; Toschi L; Rossi S; Finocchiaro G; Grizzi F; Mazziotti E; Qehajaj D; Rahal D; Lopci E
Clin Lung Cancer; 2020 Jan; 21(1):28-36. PubMed ID: 31409523
[TBL] [Abstract][Full Text] [Related]
25. Nodal metabolic tumour volume on baseline
Alipour R; Bucknell N; Bressel M; Everitt S; MacManus M; Siva S; Hofman MS; Akhurst T; Hicks RJ; Iravani A
J Med Imaging Radiat Oncol; 2021 Oct; 65(6):748-754. PubMed ID: 34318603
[TBL] [Abstract][Full Text] [Related]
26. 18F-FDG PET/CT in non-small-cell lung cancer patients: a potential predictive biomarker of response to immunotherapy.
Evangelista L; Cuppari L; Menis J; Bonanno L; Reccia P; Frega S; Pasello G
Nucl Med Commun; 2019 Aug; 40(8):802-807. PubMed ID: 31045745
[TBL] [Abstract][Full Text] [Related]
27. The predictive value of
Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
[TBL] [Abstract][Full Text] [Related]
28. Tumor metabolic and secondary lymphoid organ metabolic markers on 18F-fludeoxyglucose positron emission tomography predict prognosis of immune checkpoint inhibitors in advanced lung cancer.
Jin P; Bai M; Liu J; Yu J; Meng X
Front Immunol; 2022; 13():1004351. PubMed ID: 36341372
[TBL] [Abstract][Full Text] [Related]
29. Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics.
Seban RD; Nemer JS; Marabelle A; Yeh R; Deutsch E; Ammari S; Moya-Plana A; Mokrane FZ; Gartrell RD; Finkel G; Barker L; Bigorgne AE; Schwartz LH; Saenger Y; Robert C; Dercle L
Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2298-2310. PubMed ID: 31346755
[TBL] [Abstract][Full Text] [Related]
30. The Role of 18F-FDG PET/CT on Staging and Prognosis in Patients with Small Cell Lung Cancer.
Zer A; Domachevsky L; Rapson Y; Nidam M; Flex D; Allen AM; Stemmer SM; Groshar D; Bernstine H
Eur Radiol; 2016 Sep; 26(9):3155-61. PubMed ID: 26685851
[TBL] [Abstract][Full Text] [Related]
31. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
32. Prospective Study of Serial Imaging Comparing Fluorodeoxyglucose Positron Emission Tomography (PET) and Fluorothymidine PET During Radical Chemoradiation for Non-Small Cell Lung Cancer: Reduction of Detectable Proliferation Associated With Worse Survival.
Everitt S; Ball D; Hicks RJ; Callahan J; Plumridge N; Trinh J; Herschtal A; Kron T; Mac Manus M
Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):947-955. PubMed ID: 29063854
[TBL] [Abstract][Full Text] [Related]
33. The immune-metabolic-prognostic index and clinical outcomes in patients with non-small cell lung carcinoma under checkpoint inhibitors.
Castello A; Toschi L; Rossi S; Mazziotti E; Lopci E
J Cancer Res Clin Oncol; 2020 May; 146(5):1235-1243. PubMed ID: 32048008
[TBL] [Abstract][Full Text] [Related]
34. Prognostic significance of semi-quantitative FDG-PET parameters in stage I non-small cell lung cancer treated with carbon-ion radiotherapy.
Shrestha S; Higuchi T; Shirai K; Tokue A; Shrestha S; Saitoh JI; Hirasawa H; Ohno T; Nakano T; Tsushima Y
Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1220-1227. PubMed ID: 31758225
[TBL] [Abstract][Full Text] [Related]
35. Metabolic tumor burden on baseline
Chen S; He K; Feng F; Wang S; Yin Y; Fu H; Wang H
Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1830-1839. PubMed ID: 31187163
[TBL] [Abstract][Full Text] [Related]
36. Prognostic Value of Volumetric Parameters on Staging and Posttreatment FDG PET/CT in Patients With Stage IV Non-Small Cell Lung Cancer.
Lee JW; Lee SM; Yun M; Cho A
Clin Nucl Med; 2016 May; 41(5):347-53. PubMed ID: 26825204
[TBL] [Abstract][Full Text] [Related]
37. [Prognostic value of (18)F-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT) in extensive-stage small cell lung cancer].
Ding CY; Guo Z; Li YY; Li TR
Zhonghua Zhong Liu Za Zhi; 2017 Nov; 39(11):828-834. PubMed ID: 29151289
[No Abstract] [Full Text] [Related]
38. Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection.
Hyun SH; Choi JY; Kim K; Kim J; Shim YM; Um SW; Kim H; Lee KH; Kim BT
Ann Surg; 2013 Feb; 257(2):364-70. PubMed ID: 22968069
[TBL] [Abstract][Full Text] [Related]
39. Long-term Survival with 18-Fluorodeoxyglucose Positron Emission Tomography-directed Therapy in Non-small Cell Lung Cancer with Synchronous Solitary Brain Metastasis.
Newman S; Bucknell N; Bressel M; Tran P; Campbell BA; David S; Haghighi N; Hanna GG; Kok D; MacManus M; Phillips C; Plumridge N; Shaw M; Wirth A; Wheeler G; Ball D; Siva S
Clin Oncol (R Coll Radiol); 2021 Mar; 33(3):163-171. PubMed ID: 33129655
[TBL] [Abstract][Full Text] [Related]
40. Prognostic significance of metabolic parameters measured by
Chang H; Lee SJ; Lim J; Lee JS; Kim YJ; Lee WW
J Cancer Res Clin Oncol; 2019 May; 145(5):1361-1367. PubMed ID: 30900157
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]